Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Endometrial Cancer

Clinical Trial at: Compass Oncology - Vancouver

D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

  • Details

ClinicalTrials.gov ID: NCT04269200
Diagnosis Type: Endometrial Cancer
USOR Number: 19221

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Endometrial Cancer

Clinical Trial at: Compass Oncology - Portland

D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

  • Details

ClinicalTrials.gov ID: NCT04269200
Diagnosis Type: Endometrial Cancer
USOR Number: 19221

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Endometrial Cancer

Clinical Trial at: Compass Oncology - Portland

D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

  • Details

ClinicalTrials.gov ID: NCT04269200
Diagnosis Type: Endometrial Cancer
USOR Number: 19221

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page

Endometrial Cancer

Clinical Trial at: Compass Oncology - Tigard

D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

  • Details

ClinicalTrials.gov ID: NCT04269200
Diagnosis Type: Endometrial Cancer
USOR Number: 19221

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Vancouver

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

  • Details

ClinicalTrials.gov ID: NCT04222972
Diagnosis Type: Lung Cancer
USOR Number: 19208

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Tigard

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

  • Details

ClinicalTrials.gov ID: NCT04222972
Diagnosis Type: Lung Cancer
USOR Number: 19208

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Portland

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

  • Details

ClinicalTrials.gov ID: NCT04222972
Diagnosis Type: Lung Cancer
USOR Number: 19208

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Portland

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

  • Details

ClinicalTrials.gov ID: NCT04222972
Diagnosis Type: Lung Cancer
USOR Number: 19208

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Tigard

A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY,IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1-SELECTED NON-SMALL CELL LUNG CANCER (GO41717)

  • Details

ClinicalTrials.gov ID: NCT04294810
Diagnosis Type: Lung Cancer
USOR Number: 19192

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Vancouver

A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY,IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1-SELECTED NON-SMALL CELL LUNG CANCER (GO41717)

  • Details

ClinicalTrials.gov ID: NCT04294810
Diagnosis Type: Lung Cancer
USOR Number: 19192

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page
1 2 3 … 12

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.